Clinical Trials Browser

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Solid Malignant Tumors

Neoplasm Metastasis, Sarcoma

Carcinoma, Hepatocellular

Liver Metastasis Colon Cancer

Esophageal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

MSI-H Colorectal Cancer

Colorectal Neoplasms

Carcinoma, Hepatocellular

Colorectal Neoplasms

Carcinoma, Hepatocellular

Neoplasm Metastasis

Osteosarcoma

Chondroma, Chondrosarcoma, Osteosarcoma

Thyroid Neoplasms

Carcinoma, Adenoid Cystic

Gastrointestinal Stromal Tumors

Carcinoma, Hepatocellular

Colorectal Neoplasms

Ovarian Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Glioblastoma

Colonic Neoplasms

Carcinoma, Hepatocellular, Liver Neoplasms

Colorectal Neoplasms

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Rectal Neoplasms

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Glioblastoma

Advanced Colorectal Cancer in the Third-line Treatment and Beyond

Colorectal Neoplasms

Carcinoma, Hepatocellular

Clinical Trials

TAPUR

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

EREMISS

REGO-SARC

Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib

DREAM

A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

PARERE

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma

STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

MegaMOST

SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

REGOBONE

A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

LEAF-02

Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma

Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC

Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

x-МАР

SED-RO-ICC

Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.

SOREGATT

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC